In this trial, patients with active RA who were at risk for cardiovascular events, such as smoking, were assigned to one of three treatment groups: TNF inhibitors, or 5 mg of tofacitinib twice daily, or 10 mg twice daily, and observed for 5 years. Here, TNF is linked to rheumatoid arthritis.